Telix Pharmaceuticals (ASX: TLX) jumps 16% after CMS greenlight and Illuccix’s European rollout

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) has raised its full-year 2025 revenue guidance to a range of $800 million to $820 million, reflecting increased commercial uptake of its radiopharmaceutical portfolio and new regulatory milestones in both the United States and Europe. This marks a $30 million uplift from its previous guidance, underpinned by a 53% year-over-year revenue surge in Q3 2025 to $206 million.

This performance comes amid renewed interest in diagnostic and therapeutic radiopharmaceuticals, particularly in oncology imaging. Telix’s strategic focus on PSMA-targeted agents and the broader expansion of its pipeline and manufacturing base appear to be strengthening its operational and revenue trajectory at a time when many biotech peers are scaling back. Institutional sentiment, reflected in an ASX share price rally of 16.3% on October 14, signals a possible inflection in investor confidence following a year-long downtrend that saw Telix lose nearly 24% of its market value.

What does CMS reimbursement for Gozellix mean for Telix’s market positioning in the United States?

Telix Pharmaceuticals achieved a major regulatory milestone with full reimbursement approval for Gozellix, its gallium-68 gozetotide-based PSMA imaging agent. The Centers for Medicare and Medicaid Services (CMS) granted the product a Level II HCPCS code and Transitional Pass-Through (TPT) payment status, effective October 1, 2025. This follows the earlier U.S. Food and Drug Administration (FDA) approval for Gozellix and places Telix in a uniquely advantageous position as the only biopharmaceutical company with two FDA-cleared PSMA imaging agents—Illuccix and Gozellix—on the U.S. market.

Telix Pharmaceuticals Managing Director and Group CEO Dr. Christian Behrenbruch described the update as a “solid result,” highlighting that the dual-product strategy allows for greater pricing flexibility, manufacturing redundancy, and enhanced customer choice based on reimbursement pathways. A 3% increase in dose volumes over the previous quarter also suggests that pricing headwinds in the radiopharmaceutical segment may be easing, which could provide further margin tailwinds into Q4 and FY26.

How has the European expansion of Illuccix contributed to revenue and global footprint in Q3?

The commercial footprint of Illuccix has now expanded across all 19 European Union countries included in Telix’s decentralized procedure submission. The product has already launched commercially in the United Kingdom, Germany, France, Finland, Sweden, Norway, and Denmark, with additional markets to follow as reimbursement is secured.

The strategic significance of Illuccix’s European rollout cannot be overstated. It positions Telix Pharmaceuticals to diversify away from U.S.-centric revenue and tap into a multi-billion-dollar prostate cancer diagnostics market in Europe. Moreover, Telix’s parallel development of the BiPASS study—a Phase 3 trial combining magnetic resonance imaging and PSMA-PET to reduce unnecessary biopsies—could unlock further clinical utility for Illuccix and Gozellix, enhancing their reimbursement value in both U.S. and international markets.

What were the headline financial metrics for Q3 2025 and how do they stack up against the previous year?

Telix Pharmaceuticals reported unaudited group revenue of $206 million for the quarter ended September 30, 2025. This represents a 53% increase compared to $135 million in Q3 2024 and a 1% sequential increase from Q2 2025. PSMA imaging revenue—including both Illuccix and Gozellix—came in at $155 million, up 17% year-over-year. Third-party revenue from the recently acquired RLS radiopharmacies added $47 million, with the figure essentially flat compared to the previous quarter.

Despite these strong topline numbers, Telix’s trailing 12-month share return remained negative at -23.88%, with market watchers citing the company’s high price-to-earnings ratio of 463.89 as a factor tempering enthusiasm. However, the recent sharp price appreciation and ASX rank of 116 out of 2,297 stocks—ninth in the healthcare sector—suggest that institutional appetite is returning amid consistent revenue execution and product-level differentiation.

What is the status of Telix’s late-stage therapeutics pipeline and which trials are moving into pivotal stages?

The company’s lead therapeutic asset, TLX591, has progressed into Part 2 of its global Phase 3 trial for prostate cancer (ProstACT Global). While patient enrollment for Part 1 has concluded, a preliminary readout on safety and dosimetry is expected following treatment completion and data analysis. Part 2 is now actively enrolling in Australia, New Zealand, and Canada, with regulatory approvals in place for China, Singapore, Türkiye, and Japan.

In renal cancer, Telix Pharmaceuticals received ethics approval in Australia to begin LUTEON, a pivotal trial for TLX250 as a monotherapy in metastatic clear cell renal cell carcinoma (ccRCC). The STARLITE-1 trial has already commenced dosing for TLX250 in combination with cabozantinib and nivolumab. Meanwhile, in brain cancer, Telix has activated the first site in Australia for the IPAX-BrIGHT trial, its international pivotal study of TLX101 in recurrent glioblastoma, following European ethics approval.

The company is also preparing to dose the first patient in SOLACE, a Phase 1 trial for TLX090 in bone pain associated with osteoblastic metastases. Separately, TLX400, a Fibroblast Activation Protein (FAP)-targeting therapy for sarcoma, demonstrated early signs of antitumor activity and a favorable safety profile in a clinical study published in the Journal of Nuclear Medicine.

How is Telix Pharmaceuticals advancing its non-oncology imaging agents and regulatory filings for Pixclara and Zircaix?

Telix Pharmaceuticals has made progress in expanding its imaging pipeline beyond prostate and bone cancer. For Pixclara, the company reached an agreement with the FDA on the resubmission path for its New Drug Application (NDA) and confirmed plans to file during Q4 2025. The candidate targets brain cancer using 18F-floretyrosine (18F-FET) imaging.

Meanwhile, Zircaix—Telix’s kidney cancer imaging agent using 89Zr-DFO-girentuximab—received a Complete Response Letter from the FDA in August 2025. Telix Pharmaceuticals is now preparing for a Type A meeting to address outstanding issues before refiling its Biologics License Application (BLA).

These developments highlight the company’s ambitions to build a diversified diagnostic suite capable of supporting personalized therapy decisions across multiple cancer types.

How will Telix’s in-house manufacturing in Australia and Japan strengthen isotope supply and long-term revenue scalability?

Telix has secured radiation licenses for two of its proprietary manufacturing facilities—TMS North Melbourne in Australia and TMS Yokohama in Japan. These facilities are nearing operational readiness and are designed to support the production of a broad range of medical isotopes for both clinical trials and commercial use.

This vertical integration gives Telix Pharmaceuticals control over its supply chain and opens up potential new revenue channels as a radiopharmaceutical contract manufacturing partner. It also serves as a strategic hedge against global isotope supply disruptions, which have historically impacted the radiopharmaceutical industry.

How does the ANMI royalty buyout streamline Telix’s long-term cost structure?

In July 2025, Telix Pharmaceuticals made a final royalty and option payment of $51.7 million to Advanced Nuclear Medicine Ingredients (ANMI), the original developer of the Illuccix technology acquired in 2018. This payment covers the third and final annual variable obligation and completes the company’s contractual financial commitments to ANMI. The transaction will be reflected in Telix’s H2 2025 cash flow and removes a variable cost line from future earnings, improving clarity on gross margin performance moving forward.

How is investor sentiment evolving after Telix’s Q3 report and what indicators should be tracked next?

Following the Q3 earnings release and upward guidance revision, Telix Pharmaceuticals shares rose by 16.3% to AUD 16.70, on a trading volume exceeding 5.38 million shares. While the 12-month return remains negative, recent momentum suggests that institutional investors are revisiting Telix’s valuation, particularly as it consolidates its position in PSMA imaging and advances multiple late-stage clinical programs.

Investor focus in the coming quarters is likely to center on dose volume trends in the U.S., trial data readouts from ProstACT and LUTEON, FDA interactions for Pixclara and Zircaix, and the operational launch of Telix’s manufacturing facilities. The company’s 20–25% increase in R&D spending for FY25 also reflects a forward-leaning strategy likely to appeal to long-term growth-focused investors.